CRMD vs. ENTA, CTNM, EPIX, BDTX, XOMA, VRCA, KMDA, NBTX, VNDA, and INZY
Should you be buying CorMedix stock or one of its competitors? The main competitors of CorMedix include Enanta Pharmaceuticals (ENTA), Contineum Therapeutics (CTNM), ESSA Pharma (EPIX), Black Diamond Therapeutics (BDTX), XOMA (XOMA), Verrica Pharmaceuticals (VRCA), Kamada (KMDA), Nanobiotix (NBTX), Vanda Pharmaceuticals (VNDA), and Inozyme Pharma (INZY). These companies are all part of the "medical" sector.
Enanta Pharmaceuticals (NASDAQ:ENTA) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, community ranking, risk, earnings, valuation and institutional ownership.
Enanta Pharmaceuticals received 294 more outperform votes than CorMedix when rated by MarketBeat users. However, 70.00% of users gave CorMedix an outperform vote while only 56.41% of users gave Enanta Pharmaceuticals an outperform vote.
CorMedix has a net margin of 0.00% compared to CorMedix's net margin of -187.77%. CorMedix's return on equity of -60.38% beat Enanta Pharmaceuticals' return on equity.
In the previous week, Enanta Pharmaceuticals had 10 more articles in the media than CorMedix. MarketBeat recorded 11 mentions for Enanta Pharmaceuticals and 1 mentions for CorMedix. Enanta Pharmaceuticals' average media sentiment score of 0.98 beat CorMedix's score of 0.32 indicating that CorMedix is being referred to more favorably in the news media.
Enanta Pharmaceuticals has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500.
95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 13.6% of Enanta Pharmaceuticals shares are held by insiders. Comparatively, 4.6% of CorMedix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
CorMedix has lower revenue, but higher earnings than Enanta Pharmaceuticals. CorMedix is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Enanta Pharmaceuticals presently has a consensus target price of $19.33, indicating a potential upside of 32.42%. CorMedix has a consensus target price of $13.00, indicating a potential upside of 120.71%. Given Enanta Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe CorMedix is more favorable than Enanta Pharmaceuticals.
Summary
CorMedix beats Enanta Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get CorMedix News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CorMedix Competitors List
Related Companies and Tools
